Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI dye could reveal hidden brain artery inflammation

NCT ID NCT03084523

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tested whether a special MRI contrast agent called ferumoxytol can detect inflammation in brain arteries of people who recently had a stroke. Researchers compared it to standard gadolinium contrast in 30 participants with narrowed brain arteries. The goal was to see if ferumoxytol highlights inflamed areas better, which could help prevent future strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ferumoxytol (Feraheme) injectable MRI contrast agent
What this could lead to
If successful, this could lead to better imaging methods to identify inflamed brain arteries, potentially improving stroke prevention strategies.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply broadly. The new contrast agent may not show inflammation better than standard methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

30 people

The number who actually took part.

Started

Apr 2017

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

80 patients will be enrolled in this prospective cross-sectional study of Intracranial atherosclerosis. * Inclusion Criteria: * intracranial atherosclerosis (stenosis ≥50%) * recent ischemic stroke (less than or equal to 14 days) * Exclusion Criteria: * Less than 18 years old * Documented history of atrial fibrillation * Carotid stenosis greater than 70% * Pregnant women * Contrast allergy * Acute or chronic kidney disease with glomerular filtration rate\<30 ml/min/1.73m2 * Intravenous iron sensitivity * Serum ferritin and transferrin saturation above age-adjusted upper limit of normal. If serum ferritin is above normal, but transferrin saturation is normal, the patient is not excluded. * Pacemaker or other MRI contraindications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral atherosclerosis intracranial arteriosclerosis ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial atherosclerosis Stroke

Contacts and locations

Locations

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.